 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 01/09/2008 | | | | Expert Review of Molecular Diagnostics Publishes Positive Report on Nymox Alzheimer Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
January 9, 2008: Nymox announces the publication of a positive peer-reviewed paper on the clinical utility of the Company’s AlzheimAlert™ urine test as an aid to physicians in the diagnosis of Alzheimer’s disease in the current issue of Expert Review of Molecular Diagnostics (January 2008; 8:21-28). |
| 12/12/2007 | | | | Nymox Reports Update on NX-1207 Study Results, Marketing Plans and Activities
topic: R&D: BPH (enlarged prostate) Treatments
December 12, 2007: Nymox reported today an update on recent study results and development activities for the Company’s NX-1207 drug for benign prostatic hyperplasia (BPH). The results of the recently completed 2 year double blind follow-up study demonstrated the durable effect of the drug, which is of fundamental interest and importance to urologists and their patients. The study was conducted at 24 U.S. sites and involved 103 unselected patients. |
| 11/28/2007 | | | | Nymox Announces Positive Results in New 2 Year Blinded, Placebo Controlled Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
November 28, 2007: Nymox today announced positive results from a newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 24 clinical trial sites across the U.S. and 103 unselected subjects participated in the blinded, placebo controlled study. |
| 11/14/2007 | | | | Nymox Reports Completion of Large New 2 Year Follow-up Study of
topic: R&D: BPH (enlarged prostate) Treatments
November 14, 2007: Nymox announced today completion of a large new 2 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of over one hundred subjects involved in the Company’s Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 2 years after
NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. |
| 11/13/2007 | | | | Nymox Reports Third Quarter Financial Results for 2007
topic: Financial
November 13, 2007: Nymox Pharmaceutical Corporation announced today its financial results for the quarter ended September 30, 2007. |
| 10/24/2007 | | | | Nymox Announces Clinical Study Presentation on New BPH Drug at Upcoming American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
October 24, 2007: Nymox today announced that clinical trial data from the Company’s long term studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Western Section of the American Urological Association Meeting in Scottsdale, Arizona next week on October 30. |
| 10/11/2007 | | | | Nymox Announces New BPH Drug Long Term Follow-up Study Clinical Data Presentation October 20 at American Urological
topic: R&D: BPH (enlarged prostate) Treatments
October 11, 2007: Nymox today announced that new follow-up study clinical trial data from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Mid-Atlantic Section of the American Urological Association Meeting in Hamilton, Bermuda next week on October 20. |
| 09/27/2007 | | | | Nymox Announces BPH Drug Clinical Data Presentation September 28 at American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
September 27, 2007: Nymox today announced that clinical trial data from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the New England Section of the American Urological Association Meeting in Boston this week on September 28. |
| 09/18/2007 | | | | Nymox Saliva Test Strongly Supported By New Independent Study Data Published in Cancer Epidemiology Biomarkers & Prevention
topic: Tobacco Exposure Tests
September 18, 2007: Nymox announced the new publication of an independent study reporting positive data on the accuracy and usefulness of the Company's Saliva NicAlert™ test for tobacco exposure in a family practice setting. The paper, “Validation of Self-Reported Smoking Status Using Saliva Cotinine: A Rapid Semiquantitative Dipstick Method,” (Cancer Epidemiol Biomarkers Prev. Sep 2007;16:1858-62) is in the current issue of Cancer Epidemiology Biomarkers & Prevention, published by the American Association for Cancer Research (AACR) and is co-authored by principal investigators, Dr. Norman J. Montalto and Dr. Wayne O. Wells, both physicians with long-standing interest and expertise in the field of tobacco use and dependency. |
| 09/06/2007 | | | | Nymox BPH Drug Data Presentation September 8 at American Urological Association Meeting
topic: R&D: BPH (enlarged prostate) Treatments
September 6, 2007: Nymox today announced that clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia will be presented at the South Central American Urological Association Meeting in Colorado Springs this weekend on September 8. |
|